HC Wainwright Reaffirms “Buy” Rating for Zevra Therapeutics (NASDAQ:ZVRA)

by · The Cerbat Gem

HC Wainwright restated their buy rating on shares of Zevra Therapeutics (NASDAQ:ZVRA – Free Report) in a research report sent to investors on Monday, Benzinga reports. HC Wainwright currently has a $20.00 target price on the stock. HC Wainwright also issued estimates for Zevra Therapeutics’ Q3 2024 earnings at ($0.50) EPS, Q4 2024 earnings at ($0.37) EPS, FY2024 earnings at ($1.74) EPS, FY2025 earnings at ($0.30) EPS, FY2026 earnings at $0.59 EPS, FY2027 earnings at $2.27 EPS and FY2028 earnings at $2.71 EPS.

Other research analysts have also recently issued reports about the company. Cantor Fitzgerald reissued an overweight rating on shares of Zevra Therapeutics in a report on Wednesday, August 14th. JMP Securities began coverage on Zevra Therapeutics in a research report on Tuesday, September 24th. They issued an outperform rating and a $17.00 price objective for the company. Canaccord Genuity Group lowered their price objective on Zevra Therapeutics from $24.00 to $22.00 and set a buy rating for the company in a research report on Wednesday, September 18th. Maxim Group lifted their price objective on Zevra Therapeutics from $18.00 to $25.00 and gave the stock a buy rating in a research report on Tuesday, September 24th. Finally, Roth Mkm lifted their price objective on Zevra Therapeutics from $19.00 to $21.00 and gave the stock a buy rating in a research report on Tuesday, September 24th. Six analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of Buy and an average price target of $21.00.

Check Out Our Latest Stock Report on ZVRA

Zevra Therapeutics Stock Up 3.9 %

Shares of ZVRA stock opened at $7.12 on Monday. The stock has a market cap of $297.99 million, a P/E ratio of -5.27 and a beta of 1.94. Zevra Therapeutics has a one year low of $3.89 and a one year high of $8.95. The stock has a fifty day moving average price of $7.18 and a 200 day moving average price of $5.77. The company has a debt-to-equity ratio of 1.80, a current ratio of 2.00 and a quick ratio of 2.00.

Zevra Therapeutics (NASDAQ:ZVRA – Get Free Report) last issued its earnings results on Tuesday, August 13th. The company reported ($0.48) EPS for the quarter, missing the consensus estimate of ($0.47) by ($0.01). The firm had revenue of $4.45 million during the quarter, compared to the consensus estimate of $4.08 million. Zevra Therapeutics had a negative return on equity of 124.85% and a negative net margin of 274.10%. During the same period last year, the business earned ($0.15) earnings per share. Analysts predict that Zevra Therapeutics will post -1.59 earnings per share for the current year.

Insider Activity

In other Zevra Therapeutics news, Director Thomas Anderson acquired 10,000 shares of the business’s stock in a transaction dated Tuesday, July 16th. The shares were acquired at an average price of $6.81 per share, for a total transaction of $68,100.00. Following the acquisition, the director now directly owns 20,000 shares of the company’s stock, valued at approximately $136,200. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders have acquired 22,000 shares of company stock worth $140,340 in the last 90 days. Corporate insiders own 2.40% of the company’s stock.

Hedge Funds Weigh In On Zevra Therapeutics

Institutional investors have recently modified their holdings of the business. Vanguard Group Inc. lifted its stake in Zevra Therapeutics by 3.6% in the 1st quarter. Vanguard Group Inc. now owns 1,704,006 shares of the company’s stock valued at $9,883,000 after acquiring an additional 58,866 shares in the last quarter. Retirement Planning Co of New England Inc. lifted its stake in Zevra Therapeutics by 6.5% in the 2nd quarter. Retirement Planning Co of New England Inc. now owns 458,300 shares of the company’s stock valued at $2,246,000 after acquiring an additional 28,107 shares in the last quarter. Mystic Asset Management Inc. lifted its stake in Zevra Therapeutics by 11.9% in the 2nd quarter. Mystic Asset Management Inc. now owns 297,947 shares of the company’s stock valued at $1,460,000 after acquiring an additional 31,650 shares in the last quarter. Armistice Capital LLC bought a new stake in Zevra Therapeutics in the 4th quarter valued at approximately $1,755,000. Finally, Bank of New York Mellon Corp lifted its stake in Zevra Therapeutics by 10.7% in the 2nd quarter. Bank of New York Mellon Corp now owns 220,499 shares of the company’s stock valued at $1,080,000 after acquiring an additional 21,231 shares in the last quarter. Institutional investors own 35.03% of the company’s stock.

Zevra Therapeutics Company Profile

(Get Free Report)

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.

Featured Stories